|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The recurrent p.Gly84Glu germline mutation (G84E) in HOXB13 is consistently associated with prostate cancer (PCa), although the mechanisms underlying such linkage remain elusive.
|
30560549 |
2019 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk of 15% for noncarriers.
|
30527799 |
2019 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk of 15% for noncarriers.
|
30527799 |
2019 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The recurrent p.Gly84Glu germline mutation (G84E) in HOXB13 is consistently associated with prostate cancer (PCa), although the mechanisms underlying such linkage remain elusive.
|
30560549 |
2019 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Interplay of <i>HOXB13</i> (G84E) and <i>CIP2A</i> (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; <i>P</i> = 0.000024).
|
30181389 |
2018 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers.
|
29181843 |
2018 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Interplay of <i>HOXB13</i> (G84E) and <i>CIP2A</i> (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; <i>P</i> = 0.000024).
|
30181389 |
2018 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
While there was a trend toward an earlier age at diagnosis, overall the clinicopathologic features of PCa were not significantly different in G84E carriers and non-carriers.
|
29181843 |
2018 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant plays in P</span>Ca development is unknown.
|
29259341 |
2017 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The HOXB13 G84E variant is associated with risk of prostate cancer (PCa), however the role this variant plays in P</span>Ca development is unknown.
|
29259341 |
2017 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
We identified 101 heterozygous carriers of G84E who underwent radical prostatectomy for prostate cancer between 1985 and 2011 and matched these men by race, age and tumor grade to 99 HOXB13 wild-type controls.
|
28186998 |
2017 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results indicated that significant increased PCa susceptibility was associated with rs138213197 compared with non-carriers (OR = 3.38, 95% CI: 2.45-4.66).
|
27626483 |
2016 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The prostate cancer risk allele p.G84E was identified in 18 (0.56%) of 3,187 cases and 16 (0.70%) of 2,300 controls (OR = 0.81, 95% CI = 0.41-1.59, P = 0.54).
|
27424772 |
2016 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The prostate cancer risk allele p.G84E was identified in 18 (0.56%) of 3,187 cases and 16 (0.70%) of 2,300 controls (OR = 0.81, 95% CI = 0.41-1.59, P = 0.54).
|
27424772 |
2016 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The HOXB13 G84E mutation was identified in 0.49% of controls and in 2.51% of PCa cases.
|
26779768 |
2016 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The HOXB13 G84E mutation was identified in 0.49% of controls and in 2.51% of PCa cases.
|
26779768 |
2016 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our results indicated that significant increased PCa susceptibility was associated with rs138213197 compared with non-carriers (OR = 3.38, 95% CI: 2.45-4.66).
|
27626483 |
2016 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The age-specific risk of prostate cancer among G84E mutation carriers was higher than among non-carriers.
|
25629170 |
2015 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The clinical importance of HOXB13 G84E in PrCa management has not been established.
|
25595936 |
2015 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Our study confirms the association between the HOXB13 G84E variant and prostate cancer and suggests a novel association between G84E and leukemia and a suggestive association with bladder cancer.
|
26108461 |
2015 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Then, 25 studies including 51,390 cases and 93,867 controls were included, and there was significant association between HOXB13 p.Gly84Glu mutation and overall cancer risk (OR = 2.872, 95% CI = 2.121-3.888, P < 0.001), particularly in prostate cancer (OR = 3.248, 95% CI = 2.313-4.560, P < 0.001), while no association was found in breast (OR = 1.424, 95% CI = 0.776-2.613, P = 0.253) and colorectal cancers (OR = 2.070, 95% CI = 0.485-8.841, P = 0.326).
|
26517352 |
2015 |
|
Malignant neoplasm of prostate
|
|
0.800 |
GeneticVariation
|
BEFREE |
The age-specific risk of prostate cancer among G84E mutation carriers was higher than among non-carriers.
|
25629170 |
2015 |
|
Prostate carcinoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The clinical importance of HOXB13 G84E in PrCa management has not been established.
|
25595936 |
2015 |